HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, No. 5, May 2016 – Healthcare Systems & Policies in Asia       » Understanding Healthcare Policies in the Philippines: Cancer Care       » Young Innovators under 35       » Healthcare Cost Effectiveness in Singapore       » ASLAN Pharmaceuticals Opens China Office       » A Journey Inside the Human Body       » Treatment Brings New Hope for Patients Suffering From Fatal Lung Disease      
BIOBOARD - SINGAPORE
Singapore Scientists Lead in the Discovery of Gene Responsible for Fatal Drug Allergy

A team of researchers led by Prof Liu Jianjun from A*STAR鈥檚 Genome Institute of Singapore (GIS) has discovered that the presence of a gene allele known as HLA-B*13:01 could cause a severe adverse drug reaction (ADR) to dapsone, which could be fatal. The important discovery will lead to the development of HLA-B*13:01-based diagnostic tests, which will identify high-risk individuals of this potentially life-threatening condition, and help improve the safety of dapsone therapy.

Dapsone (diamino-diphenyl sulfone) is a drug used in the treatment of various forms of infectious and inflammatory diseases and is commonly prescribed for the treatment of leprosy. Up to 3.6% of individuals treated with dapsone develop a severe adverse drug reaction known as dapsone hypersensitivity syndrome (DHS) and between 11% and 13% die as a result. This is alarming as no test is currently available to predict the risk of DHS in patients.

Prof Liu, Senior Group Leader of Human Genetics and Deputy Director of Research Programmes at the GIS, and his colleagues performed a genome-wide association study on 76 DHS patients and 1,304 controls, and discovered that the presence of a particular HLA-B molecule (called HLA-B*13:01) increased the risk of DHS. Individuals carrying a single copy of HLA-B*13:01 run 34 times the risk of being hit by DHS as compared to those who do not carry this allele. The scientists further found that the risk is magnified 100 times for those who carry two copies of HLA-B*13:01.

This study also showed that the allele HLA-B*13:01 has a sensitivity and specificity of above 85% in predicting the risk of DHS. Additionally, the implementation of HLA-B*13:01-based diagnostic testing reduces the risk of DHS by an impressive seven-fold.

Click here for the complete issue.

NEWS CRUNCH  
news World Immunisation Week 2016
news IoT Asia 2016 Delivers Actionable Solutions for a Sustainable IoT Ecosystem in Asia
news Lite-On presents a new Biomedical Research and Development Centre in Singapore
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  
APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Leading-Edge ONCOLOGY
May:
Healthcare Systems & Policies in Asia
June:
Medical Devices and Digital Health Technology
July:
Water Technology
August:
Guest Editorial - Antibody Informatics In Japan
September:
Infectious Diseases
October:
Medical Tourism
November:
Biomedical Imaging Technology
December:
Food Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim/td>
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy